External validation of anti-Müllerian hormone based prediction of live birth in assisted conception by Khader, A. et al.
  
 
 
 
 
Khader, A., Lloyd, S.M., McConnachie, A., Fleming, R., Grisendi, V., La 
Marca, A., and Nelson, S.M. (2013) External validation of anti-Müllerian 
hormone based prediction of live birth in assisted conception. Journal of 
Ovarian Research, 6 (3). ISSN 1757-2215 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/75681/ 
 
 
 
 
Deposited on: 21th February 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Khader et al. Journal of Ovarian Research 2013, 6:3
http://www.ovarianresearch.com/content/6/1/3RESEARCH Open AccessExternal validation of anti-Müllerian
hormone based prediction of live
birth in assisted conception
Amani Khader1, Suzanne M Lloyd2, Alex McConnachie2, Richard Fleming3, Valentina Grisendi4,
Antonio La Marca4 and Scott M Nelson1*Abstract
Background: Chronological age and oocyte yield are independent determinants of live birth in assisted
conception. Anti-Müllerian hormone (AMH) is strongly associated with oocyte yield after controlled ovarian
stimulation. We have previously assessed the ability of AMH and age to independently predict live birth in an Italian
assisted conception cohort. Herein we report the external validation of the nomogram in 822 UK first in vitro
fertilization (IVF) cycles.
Methods: Retrospective cohort consisting of 822 patients undergoing their first IVF treatment cycle at Glasgow
Centre for Reproductive Medicine. Analyses were restricted to women aged between 25 and 42 years of age.
All women had an AMH measured prior to commencing their first IVF cycle. The performance of the model was
assessed; discrimination by the area under the receiver operator curve (ROCAUC) and model calibration by the
predicted probability versus observed probability.
Results: Live births occurred in 29.4% of the cohort. The observed and predicted outcomes showed no evidence of
miscalibration (p = 0.188). The ROCAUC was 0.64 (95% CI: 0.60, 0.68), suggesting moderate and similar discrimination
to the original model. The ROCAUC for a continuous model of age and AMH was 0.65 (95% CI 0.61, 0.69), suggesting
that the original categories of AMH were appropriate.
Conclusions: We confirm by external validation that AMH and age are independent predictors of live birth.
Although the confidence intervals for each category are wide, our results support the assessment of AMH in larger
cohorts with detailed baseline phenotyping for live birth prediction.
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Chronological age and oocyte yield are independent
determinants of live birth in assisted conception [1].
Circulating anti-Müllerian hormone (AMH) levels are
strongly associated with oocyte yield after controlled
ovarian stimulation [2]. This strong correlation with
oocyte yield underlies the independent associations of
AMH and age with live birth, which has now been con-
firmed in several studies [3-7]. We previously exploited
this relationship to construct a nomogram for the* Correspondence: scott.nelson@glasgow.ac.uk
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reproduction in any medium, provided the orprediction of live birth using a combination of age and
AMH in an Italian cohort of 381 IVF cycles [8].
In the original study (8), 101 of 381 women (26.5%)
achieved a live birth. Univariate and multivariate logis-
tic regression revealed significant decreasing odds of
live birth for increasing age and decreasing AMH irre-
spective of whether they were treated as continuous or
our predestined categorical variables. In order to facili-
tate the practical use of this model, a single 3×3 table
was developed (Table 1). By cross tabulating any given
patients age with their AMH level, the probability of
the live birth following IVF may be easily calculated.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The prediction model for a live birth based on
age and AMH (with permission from ref.8)
Age (years) AMH (ng/ml)
<0.4 0.4- < 2.8 ≥2.8
<31 0.13 (0.04–0.36) 0.38 (0.26–0.51) 0.52 (0.38–0.67)
31–37 0.09 (0.02–0.24) 0.27 (0.21–0.35) 0.40 (0.28–0.54)
>37 0.05 (0.01–0.16) 0.18 (0.12–0.26) 0.29 (0.17–0.44)
For each AMH and age category the probability (95% CI) of live birth after IVF
is indicated.
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aged 31–37 years and with a serum AMH levels of 0.4-
2.8 ng/ml has a 27% probability of achieving a live birth
with a confidence interval varying from 21% to 35%.
Evidence of the independent effects of age and AMH
can be seen examining the relative chance of success by
comparing categories vertically and horizontally re-
spectively. For example for the same AMH category of
0.4-2.8 ng/ml women in the age category >37 years had
a chance of live birth that was 52% lower than women
who were <31 years old. Similarly women who were
<31 years old but with very low AMH levels (<0.4 ng/
ml) had a chance of live birth decreased by 75% when
compared with women of the same age but with a high
AMH level (> 2.8 ng/ml).
At present although a variety of prediction models
have been reported, we are not aware of any other
models that incorporate AMH for the prediction of
live birth in IVF cycles (9). Our AMH-age model
therefore has the potential to become a clinically use-
ful addition to the fertility workup of infertile couples.
However before clinicians can adopt any prediction mod-
els into routine clinical practice, the accuracy of the model
should be independently evaluated in a population differ-
ent from the one on which the model was elaborated
[9,10]. External validation (EV) of the discriminative
power and calibration of the model is therefore crucial to
assess the generalizability of our model to other popula-
tions. The objective of the present study was to validate
our previously developed prediction model for the live
birth in IVF cycles in an independent large cohort of infer-
tile women.Methods
Validation cohort profile
This study analysed the database containing the clinical
and laboratory information on IVF treatment cycles car-
ried out at Glasgow Centre for Reproductive Medicine,
Glasgow 2006 – 2010. These data were collected pro-
spectively and recorded in the registered database in the
fertility centre in Glasgow, UK. Patients were stimulated
in accordance with our previously published policiesusing a combination of agonist and antagonist strategies
based on ovarian reserve assessment. For this analysis
cycles were selected for analysis if they were the first
IVF/ICSI cycle. We had previously limited our analyses
to women aged between 25 and 42 years of age (8) and
we censored the EV dataset in keeping with our previ-
ous age restriction. Embryo transfer policy was in line
with UK regulations with predominantly two embryos
transferred in women <40 and three in woman ≥40 years.
Live birth was defined as at least one infant born alive after
24 weeks gestation, consistent with previous prediction
models and publications.
AMH analysis
AMH was measured prior to commencement of all IVF
cycles and was measured on any day of the cycle. The
AMH assay used was the commercial ELISA kit pro-
vided by DSL(Webster, TX, USA), with values initially
presented in concentrations of picomoles per litre (con-
version factor to pmol/l = ng/ml × 7.143). Inter and
intra-assay coefficients of variation were 5.3 and 5.4%,
respectively. The development cohort had utilised the
Immunotech assay and therefore the EV cohort values
were transformed using our previously reported equa-
tion AMH Immunotech = 1.40 DSL–0.62 pmol/L, with
subsequent conversion to ng/ml (12). As AMH was not
normally distributed it was log transformed in accord-
ance with previous analyses.
Statistical analysis
Validation of a prediction model comprises two charac-
teristics of diagnostic performance: calibration which is
the agreement between predictions and observations in
the validation cohort and discrimination which is the
ability of the model to distinguish between women with
or without live birth.
The subjects were split into the same nine groups
based on age and logged-AMH values as previously
reported for the development cohort. The groups were
defined as follows:
1. Age > 37 & AMH < 0.4
2. Age > 37 & 0.4 ≤AMH < 2.8
3. Age > 37 & AMH ≥ 2.8
4. 31 ≤Age ≤ 37 & AMH < 0.4
5. 31 ≤Age ≤ 37 & 0.4 ≤AMH < 2.8
6. 31 ≤Age ≤ 37 & AMH ≥ 2.8
7. Age < 31 & AMH < 0.4
8. Age < 31 & 0.4 ≤AMH < 2.8
9. Age < 31 & AMH ≥ 2.8
The predicted and observed probability of live birth
for each group were derived using the respective formu-
lae (8):
Ppred live birthð Þ ¼ expð2:88þ 1:38  lnAMH0:42:8 þ 1:96  lnAMH>2:8 þ 1:01  Age<31 þ 0:52  Age31371þ exp 2:88þ 1:38  lnAMH0:42:8 þ 1:96  lnAMH>2:8 þ 1:01  Age<31 þ 0:52  Age3137ð
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The predicted number of live births was calculated for
each group by multiplying the predicted probability by the
total number of subjects in the group. The predicted num-
ber of women without a live birth was calculated as the
total number of subjects per group minus the predicted
number of live births. Groups were pooled to allow
expected counts to have >5 subjects, with comparison of
observed and predicted assessed by chi-squared test.
A.Age > 37 & AMH < 2.8
B.Age > 37 & AMH ≥ 2.8Table 2 Summary of baseline characteristics and treatment o
Characteristic Development cohort
N = 381
Age (years) 34.8 +/− 4.48
BMI (kg/m2) 24 +/− 5.8
AMH (ng/ml) 1.3 (0.03, 13.8)
Duration of infertility (years) 2.8 +/− 1.7
Cause of infertility
Combination of cause 67 (17.5%)
Endometriosis 45 (11.8%)
Idiopathic 140 (36.8%)
Male factor 123 (32.4%)
Ovulatory 82 (21.5%)
Tubal disease 57 (15.0%)
Treatment outcomes:
Duration of stimulation (days) 12.8 +/− 2.8
Dose (IU) 205 +/− 58.6
Oocytes per patient 8.5 +/− 5.1
Embryo transfers performed 347 (91.1%)
Number of embryos transferred:
0 34 (9.8%)
1 8 (2.3%)
2 83 (23.9%)
3 256 (73.8%)
Clinical pregnancy 127 (33.3%)
Live birth 101 (26.5%)
Values are presented as mean +/− SD, median (range) or n (%).
Ns: non-significant.C.31 ≤Age ≤ 37 & AMH < 2.8
D.31 ≤Age ≤ 37 & AMH ≥ 2.8
E. Age < 31 & AMH < 2.8
F. Age < 31 & AMH ≥ 2.8
The discrimination of the model was assessed by the
area under the receiver operator curve (ROCAUC), and the
calibration by the predicted probability versus observed
probability. A logistic regression model was fitted with age
and AMH as continuous variables; the discrimination of
this model was compared to that from the model with age
and AMH as categories to investigate the relative accuracy
of the age and AMH cut-offs used in the nomogram.
Analyses were performed using SASv9.2.utcomes for development and validation cohort
Validation cohort P
N = 822
35.3 +/− 4.28 Ns
24.6 +/− 4.30 <.05
2.16 (0.02, 38.6) <.05
2.49 +/− 2.36 <.05
71 (8.6%) <.05
39 (4.7%) <.05
270 (32.8%) Ns
285 (34.7%) Ns
35 (4.3%) <.05
122 (14.8%) Ns
10.4 +/− 2.11 <.05
216 +/− 59.0 <.05
7.99 +/− 4.71 Ns
713 (86.7%) <.05
109 (13.3%) Ns
127 (15.5%) <.05
534 (65.0%) <.05
52 (6.3%) <.05
264 (32.1%) Ns
242 (29.4%) Ns
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A total of 822 patients were selected on the basis of in-
clusion criteria and baseline clinical characteristics and
treatment outcomes are provided in Table 2. For con-
venience the original development cohort details are also
provided. Age was similar to the development cohort,
with AMH being significantly higher and duration of in-
fertility shorter in the EV cohort. There were differences
also in the causes of infertility as more patients with
endometriosis or ovulatory disturbances were included
in the development cohort. For the reported outcomes,
the EV cohort had significantly shorter duration of
stimulation but the number of oocytes per patient was
the same in the two groups. The number of patients
with an embryo transfer and the number of embryos
transferred were both higher in the development cohort,
however, clinical pregnancy and live birth rates were
similar (Table 2).
Predicted and observed outcomes are shown in Table 3.
There was no evidence of a difference in the observed and
predicted probabilities of live birth (p =0.188, χ2 with 6
degrees of freedom). A plot of the ratio of observed to pre-
dicted probabilities demonstrated that all confidence inter-
vals included the null, confirming that there were no
significant differences (Figure 1); the calibration plot simi-
larly suggests good calibration of the model (Figure 1).
The ROCAUC was 0.64 (95% CI: 0.60, 0.68), suggesting
only moderate discriminative ability, similar to the original
value of 0.66 (95%CI: 0.61, 0.72)(8).
Logistic regression for live birth with respect to age
and AMH, both fitted as continuous variables, demon-
strated decreased odds with increasing age (odds ratio
(OR) 0.91, 95% CI 0.87,0.94; p ≤ 0.0001), and a trend for
increased odds with higher AMH levels (OR 1.04, 95%
CI 0.99,1.09; p = 0.1297). The ROCAUC for a continuous
model of age and AMH was similar at 0.65 (95% CI
0.61, 0.69), suggesting no disadvantage to the cut-offs
employed in the nomogram.Table 3 Expected probability of a live birth based on La Marc
Probability of live bir
Age-AMH Group Covariate pattern Observed Predict
1 Age > 37; AMH < 0.4 0.0870 0.0532
2 Age > 37; AMH 0.4 - 2.8 0.1557 0.1824
3 Age > 37; AMH > = 2.8 0.2203 0.2850
4 Age 31–37; AMH < 0.4 0.1429 0.0863
5 Age 31–37; AMH 0.4 - 2.8 0.3396 0.2729
6 Age 31–37; AMH > = 2.8 0.3911 0.4013
7 Age < 31; AMH < 0.4 0.0000 0.1335
8 Age < 31; AMH 0.4 - 2.8 0.3235 0.3799
9 Age < 31; AMH > = 2.8 0.4691 0.5225Discussion
This study externally validates our AMH-age based pre-
diction of live birth for IVF [8]. Furthermore equivalent
model performance was demonstrated in the EV cohort,
with confirmation of the independent associations of
AMH and age with live birth [3-7].
Recent literature has identified an array of factors which
can influence the success of ART, with various prediction
models utilizing these factors to aid the determination of a
couple’s likelihood of success [11-13]. However, the use of
such prediction models clinically has remained limited,
largely due to lack of external validation. Of the 29 preg-
nancy prediction models identified in a recent systematic
review, only 8 were externally validated, with only 3 of these
applicable to IVF [11]. Our model adds to this literature,
allowing stratification of the probability of live birth prior to
the commencement of treatment. A relevant difference
with previous published model of live birth in IVF is that
while the majority of prediction models are based on vari-
ables measured during the IVF cycle (e.g. number and qua-
lity of embryos), the AMH-age model is based on only
baseline characteristics, hence permitting it to be used by
clinicians and patients prior to commencing stimulation.
A criticism of the original study was the cut off points
given to age and AMH levels in the nomogram and the po-
tential for predictive power of the model to be attenuated
by these designated cut-offs. In order to overcome this po-
tential weakness, we additionally investigated the use of
age and AMH as continuous variables. The ROCAUC
achieved through this mechanism was 0.65, which was
identical to that achieved originally, suggesting that the use
of the proposed cut-offs does not compromise the pre-
dicted probabilities generated and that alternative values
would not improve predictions. This is reassuring and
allows AMH and age to be displayed as categories, rather
continuous variables, in tables. This has clear benefit for
applying the model in a clinical environment, with simple
cross tabulation of the patient’s age with their AMHa model versus observed live birth
th Live birth No live birth
ed Observed Expected Observed Expected Total
2 1.22 21 21.78 23
33 38.67 179 173.3 212
13 16.81 46 42.19 59
3 1.81 18 19.19 21
72 57.85 140 154.1 212
70 71.83 109 107.2 179
0 0.13 1 0.87 1
11 12.92 23 21.08 34
38 42.32 43 38.68 81
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Figure 1 Top panel: Plot of observed/predicted probabilities of a live birth with 95% confidence intervals. No data met the criteria for
group seven. Lower panel: Calibration plot of the predicted probability versus observed probability of live birth for the nine groups, with a line of
equality. In the figure the point corresponding to zero refers to the category for which no patients met the appropriate age and AMH criteria.
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tic regression formula.
In the EV cohort the discriminative ability of the
model was only moderate (ROCAUC: 0.66), meaning that
the model has limited capacity to be able to correctly
distinguish between women who will or will not have a
baby following IVF. However, ROC curves are primarily
designed for diagnostic models (15), rather for prognos-
tic models accuracy is better assessed by examining cali-
bration (16). Calibration is evaluated by determining the
level of correspondence between the calculated preg-
nancy probabilities and the observed proportion of
pregnancies. A well-calibrated model for IVF would
be able to classify individuals into whether they have
a low, medium or high probability of achieving a live
birth. In contrast to the relatively modest discrimi-
nation, the calibration of the model was found to be
good (Figure 1).The strength of this study is that the sample size was
more than twice that used for model derivation. However,
the EV cohort differed from the original cohort for several
characteristics such as BMI and duration of infertility and
also the intermediate outcome of IVF were different be-
tween the two cohorts. This largely reflects the difference
existing between the demographic characteristics of Italian
and Scottish infertility populations and also the different
IVF clinical practices between the two countries. Particu-
larly as the initial study was undertaken when the Italian
law regulating assisted reproduction limited the number
of inseminated oocytes to three, thereby reducing the
number of embryos that may be generated for each
patient, was still operative. This resulted in a discordance
in the number of embryos transferred, with the all available
embryos being transferred in Modena – mainly three; while
single or double embryo transfer dominated in Glasgow.
In the EV cohort, women were included irrespective
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of stimulation. Despite these relatively important diffe-
rences in patient characteristics, legislation and clinical
practice the proposed model still fitted very well, further
highlighting the potential generalizability of the prognostic
model.
The original study limited its analysis to age and AMH,
as only these two factors were identified as predictive in
the original multivariate analysis for model development
(8). We are aware that additional characteristics including
BMI, cause and duration of infertility may influence
results and the lack of association of these baseline factors
with live birth, may have reflected the size of the original
cohort (14).
Finally it should be acknowledged that the probab-
ilities generated have relatively wide confidence intervals
for all groups; therefore a couple’s predicted likelihood
can range significantly. For example, women aged below
31, with AMH levels less than 0.4 ng/mL, are predicted
a 13% chance of live birth, however, the confidence
interval ranges from 4 to 36% which does not infer
much reassurance in their chances of successful out-
come. It would however be inappropriate to withhold
treatment purely based on the probability estimates
derived from our nomogram [14]. Even in women with
an AMH below or close to the functional sensitivity of
the assay, natural and assisted conception pregnancies
have been reported [15-18]. Therefore clinical consulta-
tions would require interplay of both the interpretation of
the nomogram results by the clinician and individual pa-
tient opinion as to whether the probabilities produced
could be of benefit. The greatest utility of this external
validation may therefore be to confirm that AMH is
an independent predictor of live birth and is worthy
of evaluation in larger cohorts with detailed baseline
phenotyping, with a view to assessing its utility in
improving model performance [13,19].Conclusions
This study externally validates our AMH-age based pre-
diction of live birth for IVF.
The greatest utility of this external validation may be to
confirm that AMH is an independent predictor of live
birth. Moreover, as it was shown, AMH and age can be dis-
played as categories, rather continuous variables, with clear
benefit for applying the model in a clinical environment.
However a couple’s predicted likelihood of live birth
can range significantly, therefore it would require by the
clinician interplay of both the interpretation of the
nomogram results and individual patient evaluation.
Abbreviations
AMH: Anti-Mullerian hormone; IVF: In vitro fertilization; ROCAUC: Area under
the receiver operator curve; EV: External validation; BMI: Body mass index.Competing interests
Antonio La Marca, Scott Nelson and Richard Fleming have all received
honorarium from Beckman Coulter and Roche Diagnostics to participate in
Advisory Boards regarding AMH.
Authors’ contributions
AK prepared the data and drafted the manuscript. SL and AM performed the
statistical analysis and edited the manuscript. RF provided the clinical data
and edited the manuscript. VL and AM developed the original nomogram
and edited the manuscript. SN was responsive for the project, data integrity
and final edit of the manuscript. All authors read and approved the final
manuscript.
Authors’ information
Antonio La Marca and Scott M Nelson joint senior authors.
Author details
1School of Medicine, University of Glasgow, Glasgow G12 8QQ, UK.
2Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ,
UK. 3Glasgow Centre for Reproductive Medicine, Glasgow G51 4FD, UK.
4Mother-Infant Department, Institute of Obstetrics and Gynecology,
University of Modena and Reggio Emilia, Modena 41100, Italy.
Received: 15 November 2012 Accepted: 23 December 2012
Published: 7 January 2013
References
1. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J,
Coomarasamy A: Association between the number of eggs and live birth
in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod
2011, 26:1768–1774.
2. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G,
Volpe A: Anti-Mullerian hormone (AMH) as a predictive marker in
assisted reproductive technology (ART). Hum Reprod Update 2010,
16:113–130.
3. Nelson SM, Yates RW, Fleming R: Serum anti-Mullerian hormone and FSH:
prediction of live birth and extremes of response in stimulated cycles
implications for individualization of therapy. Hum Reprod 2007,
22:2414–2421.
4. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS: Impact of female age
and male infertility on ovarian reserve markers to predict outcome of
assisted reproduction technology cycles. Reprod Biol Endocrinol 2009,
7:100.
5. Li HW, Biu Yeung WS, Lan Lau EY, Ho PC, Ng EH: Evaluating the
performance of serum antimullerian hormone concentration in
predicting the live birth rate of controlled ovarian stimulation and
intrauterine insemination. Fertil Steril 2010, 94:2177–2181.
6. Majumder K, Gelbaya TA, Laing I, Nardo LG: The use of anti-Mullerian
hormone and antral follicle count to predict the potential of oocytes
and embryos. Eur J Obstet Gynecol Reprod Biol 2010, 150:166–170.
7. Gleicher N, Weghofer A, Barad DH: Anti-Mullerian hormone (AMH) defines,
independent of age, low versus good live-birth chances in women with
severely diminished ovarian reserve. Fertil Steril 2010, 94:2824–2827.
8. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, Xella S,
Marsella T, Tagliasacchi D, D’Amico R, Volpe A: Anti-Mullerian Hormone
(AMH) based prediction model for the live birth in assisted reproductive
technology (ART). RBM online 2011, 22:341–349.
9. Moons KGM, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG,
Woodward M: Risk prediction models: II. External validation, model
updating, and impact assessment. Heart 2012, 98:691–698.
10. Altman DG, Royston P: What do we mean by validating a prognostic
model? Stat Med 2000, 19:453–473.
11. Leushuis E, van der Steeg JW, Steures P, Bossuyt PMM, Eijkemans MJC, van
der Veen F, Mol BWJ, Hompes PGA: Prediction models in reproductive
medicine: a critical appraisal. Hum Reprod Update 2009, 15:537–552.
12. Coppus SFPJ, van der Veen F, Opmeer BC, Mol BWJ, Bossuyt PMM:
Evaluating prediction models in reproductive medicine. Hum Reprod
2009, 24:1774–1778.
13. Nelson SM, Lawlor DA: Predicting live birth, preterm delivery, and low
birth weight in infants born from in vitro fertilisation: a prospective
study of 144,018 treatment cycles. PLoS Med 2011, 8:e1000386.
Khader et al. Journal of Ovarian Research 2013, 6:3 Page 7 of 7
http://www.ovarianresearch.com/content/6/1/314. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La
Marca A: Anti-Müllerian hormone: clairvoyance or crystal clear?
Hum Reprod 2012, 27:631–636.
15. Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM,
Hjollund NH, Ernst E, Bonde JP, Anderson RA, Jensen TK: Low
concentration of circulating antimullerian hormone is not predictive of
reduced fecundability in young healthy women: a prospective cohort
study. Fertil Steril 2012, 98:1602–1608.
16. Grzegorczyk-Martin V, Khrouf M, Bringer-Deutsch S, Mayenga JM, Kulski O,
Cohen-Bacrie P, Benaim JL, Belaisch-Allart J: Pronostic en fécondation
in vitro des patientes ayant une AMH basse et une FSH normale.
Gynecol Obstet Fertil 2012, 40:411–418.
17. Nelson SM, Fleming R: Low AMH and GnRH-antagonist strategies.
Fertil Steril 2009, 92:e40. author reply e41.
18. Weghofer A, Dietrich W, Barad DH, Gleicher N: Live birth chances in
women with extremely low-serum anti-Mullerian hormone levels.
Hum Reprod 2011, 26:1905–1909.
19. Lawlor DA, Nelson SM: Effect of age on decisions about the numbers of
embryos to transfer in assisted conception: a prospective study.
Lancet 2012, 379:521–527.
doi:10.1186/1757-2215-6-3
Cite this article as: Khader et al.: External validation of anti-Müllerian
hormone based prediction of live birth in assisted conception. Journal of
Ovarian Research 2013 6:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
